Amoxicillin/Clavulanate

제한된
0
C. difficile 위험도
Medium
경구생체이용률
Excellent

Dosing

Mild or moderate infectionSevere infection1.2 g IV q8h1.2 g IV q6h

Mild infectionCAP, acute otitis media, acute bacterial sinusitis250/125 mg PO q8h500/125 mg PO q8h 875/125 mg PO q12h

Age <3m & BW <4 kgAge <3m & BW ≥4 kgAge 3m-12y30 mg/kg IV q12h30 mg/kg IV q8h30 mg/kg IV q8h

Mild infectionCAP, acute otitis media, acute bacterial sinusitisAmoxicilin-based 20 mg/kg PO #3Amoxicilin-based 40 mg/kg PO #3If BW ≥40 kg, refer to adult dose

No dose adjustment

CrCl >30CrCl 10-30CrCl <10HDNo dose adjustment1.2 g IV 1 dose, then 0.6 g IV q12h1.2 g IV 1 dose, then 0.6 g IV q24hAdditional 600 mg IV after HD

CrCl >30CrCl 10-30CrCl <10HDNo dose adjustmentRecommended dose PO q12hRecommended dose PO q24hAdditional recommended dose PO after HD

General Information

Prophylaxis/treatment of bite wounds.

Polymicrobial infections of the respiratory tract or abdomen.

Skin and soft tissue infections.

Monitor CBC.

Perform culture and susceptibility tests during treatment.

During prolonged therapy, monitor renal, hepatic and hematopoietic functions.

Common

  • Rash

  • Diarrhea

  • Nausea

  • Vomiting

  • Headache

  • Vaginitis

  • Mycosis

  • Candidiasis

Serious

  • Stevens-Johnson syndrome

  • Toxic epidermal necrolysis

  • Cholestasis

  • Hepatitis

  • Hepatotoxicity

  • Anaphylaxis

  • Hypersensitivity reaction

Multiple drug-drug interactions

  • Allopurinol - increased rash

  • Probenecid

Antimicrobial class: Aminopenicillin, Beta-lactamase inhibitor

Pregnancy category: B

Average serum half life: 1 hour

Biliary penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic

Precautions:

  • Dose adjustment necessary in severe renal impairment.

  • Use caution in patients with hepatic impairment due to risk of toxicity.

  • Discontinuation may be required in Clostridium difficile-associated diarrhea or anaphylactic reactions occur.

  • Avoid use in patients with monocleosis due to increased risk for erythematous skin rash.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.